Telomir pharmaceuticals confirms telomir-1 restores vision and retinal structure in age-related macular degeneration (amd) animal model using fda-recognized surrogate endpoints

A unique oral drug candidate that is shown to restore vision and regenerate the retina in an animal model, addressing a major unmet need in ocular therapeutics miami, florida / access newswire / may 29, 2025 / telomir pharmaceuticals, inc. (nasdaq:telo) ("telomir" or the "company"), an emerging leader in age-reversal science, today announced compelling preclinical results from a study evaluating its novel oral therapeutic, telomir-1, in a genetically modified zebrafish model of age-related macular degeneration (amd). following a 14-day oral dosing regimen, telomir-1 reversed central vision response and vision acuity, restored retinal degeneration and architecture, and significantly reduced oxidative stress-achieving improvements across several fda-recognized surrogate endpoints relevant to amd.
AMD Ratings Summary
AMD Quant Ranking